ERT, a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, announced today that Robert Kleiman, M.D. has been appointed to the role of Chief Medical Officer in addition to his current role as Vice President of Global Cardiology.
Dr. Kleiman graduated from Brown University Medical School with residency in Internal Medicine and completed Fellowships in Cardiology and Cardiac Electrophysiology at the University of Pennsylvania. Prior to joining ERT as a full time employee in April 2004, Dr. Kleiman had worked for ERT as an independent contractor through his cardiology and cardiac electrophysiology practice since 1994. Dr. Kleiman has managed ERT’s cardiology group, which has more than tripled in size since 2004, while maintaining ERT’s standards for high quality and consistency.
In addition to his current duties as Vice President of Global Cardiology, Dr. Kleiman will be responsible for assuming an increasing consulting and sales role. “Dr. Kleiman combines remarkable industry expertise with years of experience in the hospital practice environment. These factors, coupled with his in-depth knowledge of our business operations, make him a perfect candidate for the position,” commented Dr. Jeffrey Litwin, President and Chief Executive Officer of ERT. “I would like to thank Bob for his dedicated service over the past eight years and congratulate him on this well deserved promotion. All of our employees look forward to continuing to work with him as he expands his role at ERT".
Commenting on his appointment Dr Kleiman noted “I have enjoyed my long association with ERT and very much look forward to working with our customers and staff in my new role of working more closely with sponsors to ensure the efficacy and safety of new drugs”.
ERT (ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations. It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company’s ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.